Predictive Oncology appoints tissue law expert David S. Smith to board

Axe Compute Inc.

David S. Smith, JD, elected to Board as Class III director, term expiring at 2024 annual meeting.
Smith fills vacancy created by resignation of Christina Jenkins, M.D. in August 2022.
Smith is a life sciences attorney and authority on legal issues around therapeutic use of human tissue and cells.
Company granted Smith shares of common stock valued at $5,000 under 2012 Stock Incentive Plan.
CEO-elect Raymond Vennare praises Smith's understanding of Predictive Oncology's proprietary biorepository.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David S. Smith

Class III director

AGPU · Axe Compute Inc.

Effective: 2022-10-19
Filed: October 25, 2022, 7:59 PM ET

Effective October 19, 2022, the Board of Directors (“Board”) of Predictive Oncology Inc. (the “Company”) elected David S. Smith, JD, to the Board as a Class III director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David S. Smith was elected as Class III director at Axe Compute Inc..

Action: elected
Role: Class III director

Exact text from the filing

Effective October 19, 2022, the Board of Directors (“Board”) of Predictive Oncology Inc. (the “Company”) elected David S. Smith, JD, to the Board as a Class III director.

View on SEC.gov

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-006726

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.